The Stanford - LPCH Vaccine Program
Historically, vaccines against infectious agents have had a more profound impact on the health of the world's population than any other advance in the biomedical sciences. Vaccine research is entering an exciting phase of expansion and innovation which is expected to yield many new approaches to disease prevention and therapy that will be useful well beyond the traditional domain of infectious diseases. For example, novel strategies using vaccines to prevent or treat cancer and allergic diseases are now being developed. New models and techniques are now available to measure the benefit and cost of vaccination in different populations. The goal of the Stanford -LPCH Vaccine Program is to ensure that our faculty has the best possible opportunity to make important contributions to progress in this field and to bring the fruits of this research to people.
The Stanford-LPCH Vaccine Program was established in 1997 with Drs. Ann Arvin and Harry Greenberg as Directors. Ann Arvin, MD, is professor of Pediatrics, Chief of the Pediatric Infectious Diseases Division and a Director of the Stanford-LPCH Vaccine Program. Dr. Greenberg is a Professor of Medicine, Senior Associate Dean - Research and Director of the Stanford-LPCH Vaccine Program. In 1999, Dr. Cornelia Dekker was appointed as the Medical Director for the Stanford-LPCH Vaccine Program to organize the clinical aspects of the program. In this regard, the Stanford-LPCH Vaccine Program has established the infrastructure to do clinical studies of vaccines in both children and adults. Collaborations with local medical groups, Vaden Student Health, and community child care centers encouraged enrollment into various clinical trials sponsored by NIH, the CDC and the pharmaceutical industry.
New Clinical Trial:
Immune Senescence in the Elderly: Comparison of Immune Responses to Influenza Vaccine in Adults of Different Age Groups
Summary The Stanford-LPCH Vaccine Program is seeking healthy adults to take part in an influenza vaccine study. You are invited to participate in a research study of the adaptive immune response to influenza (commonly known as "the flu"). We hope to discover new biological markers that are associated with age-related immune response to the seasonal flu vaccine. The flu vaccine used in this study is licensed by the FDA and is not experimental.
- Volunteers in this study will be followed for up to 3 1/2 years to establish a valuable long-term study of immune responsiveness. Identifying differences in immune function between older and younger volunteers and among individual volunteers over time may help to predict who is at highest risk for a poor immune response to the flu vaccine and perhaps to develop new therapeutic options.
- The research study will be conducted at Stanford University. Up to 30 healthy adult volunteers will be enrolled. The volunteers in this study will grouped into three age categories of 10 volunteers each: 18-30 years, 60-79 years and 80-100 years of age, inclusive.
- Dr. Cornelia L. Dekker, Professor of Pediatrics, will serve as the Principal Investigator for the Stanford-LPCH portion of the trial. The trial is sponsored by the Ellison Medical Foundation.
- If you decide to help us, three clinic visits and one phone call are required over a one month period during the fall flu season. You will receive one dose of a licensed seasonal flu vaccine at the first visit. A blood sample will be taken at each of the clinic visits. A phone follow-up will occur six months after the first visit. You will repeat the series of three clinic visits and the phone call in years 2 and 3. Participants will receive $30.00 reimbursement for each regularly scheduled clinic visit that they complete. There will be no costs for participating in the study and parking vouchers will be given.
Thank you for taking the time to learn more about our study. We look forward to the possibility of working with you. Please feel free to contact us if you have any questions.
ELIGIBILITY: We are now enrolling healthy adults who are 18 to 30 and 60-100 years of age. To see if you meet the eligibility requirements and to learn more about the visit schedule for this study, please click this link: Eligibility Criteria and Visit Schedule
FOR MORE INFORMATION:
Please contact the Stanford-LPCH Vaccine Program at (650) 498-7284, or email Vaccines_Program@stanford.edu and provide a phone number where we can reach you. (For further information regarding your rights as a participant, please call 1-866-680-2906 or write the Administrative Panel on Human Subjects in Medical Research, Administrative Panels Office, Stanford University, Stanford, CA 94305-5401.)